NL-OMON49116已完成2 期
Short-term safety, efficacy and mode of action of apremilast in mild to moderate cutaneous pemphigoid: a phase IIa open label single arm study. - SAMP trial
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •adult (>= 18 years of age) male or female patients with recently diagnosed mild
- •to moderate localized or generalized cutaneous pemphigoid, or patients that
- •were in complete remission without treatment that have a mild to moderate
- •flare-up of the disease.
排除标准
- •Women of childbearing potential without contraception; women who are pregnant
- •or planning to become pregnant or who are lactating; patients that use systemic
- •immunosuppressive medication provided the treatment cannot be stopped before
- •Visit 2; any condition which would make the patient unsuitable for treatment,
- •or requires steroid use. Patients with PHQ-9 (Patients Health Questionnaire-9)
- •score >= 10. Contradiction or known allergy for PDE4 inhibitors;
研究者
相似试验
进行中（未招募）
1 期
PDE4 inhibitor (apremilast) in pemphigoid.EUCTR2018-002564-10-NLniversitair Medisch Centrum Groningen10
已完成
2 期
Short-term safety, efficacy and mode of action of apremilast in moderate suppurative hidradenitis suppurativa: a randomised double-blind placebo controlled trial.acne ectopicaacne inversa10014982NL-OMON42894Erasmus MC, Universitair Medisch Centrum Rotterdam20
招募中
不适用
PDE4 inhibitor (apremilast) in pemphigoidNL-OMON21799MCG10
已完成
不适用
Investigation of short-term efficacy and safety of 5-alpha reductase inhibitor in the patients with BPHJPRN-UMIN000025443ara Medical University200
尚未招募
3 期
Evaluation of the Safety and Efficacy of Short-term A 002 Treatment in Subjects with Acute Coronary SyndromesHeart AttackHeart Disease10082206NL-OMON34504Anthera Pharmaceuticals, Inc576